女性、年龄与中轴型脊柱关节炎患者对肿瘤坏死因子抑制剂反应不佳:国家多中心前瞻性登记处的统计与人工智能数据分析结果
基于BIOBADASER登记处2000至2019年969例中轴型脊柱关节炎患者(女性315例、男性654例)启动TNFi治疗的数据,采用统计与人工智能分析。女性第一线TNFi治疗随访第二年达到BASDAI50反应的概率较低(P=0.018),ASDAS-CRP下降较少;逻辑回归显示女性BASDAI50反应较低(P=0.05),年龄较大(P=0.004)与不利反应相关。人工智能分析强化了治疗开始时年龄是与不利反应相关的主要因素。
要点
- 女性第一线TNFi治疗随访第二年达到BASDAI50反应的概率较低(P=0.018)。
- 逻辑回归显示女性BASDAI50反应较低(P=0.05),年龄较大(P=0.004)与不利反应相关。
- 人工智能分析显示治疗开始时年龄是与不利反应相关的主要因素。
核心结论
- 在该国家多中心登记处中,女性与第一线TNFi治疗随访第二年反应较低相关。
- 开始TNFi治疗时年龄较大是与TNFi不利反应相关的主要因素。
研究设计与样本
- 研究纳入BIOBADASER登记处(2000-2019)969例中轴型脊柱关节炎患者(女性315例、男性654例),均为启动TNFi(第一线、第二线或更后线)治疗者。
- 采用统计与人工智能(AI)数据分析,以BASDAI计算BASDAI50(BASDAI评分改善至少50%)及以C反应蛋白水平计算的ASDAS-CRP评估TNFi反应。
主要发现
- 女性第一线TNFi治疗随访第二年达到BASDAI50反应的概率较低(P=0.018),且该时间点ASDAS-CRP下降较少。
- 逻辑回归模型显示女性BASDAI50反应较低(P=0.05)。
- 年龄较大(P=0.004)与不利反应相关。
- 人工智能数据分析强化了治疗开始时年龄是与不利反应相关的主要因素这一观点。
- 年龄与其他临床特征(女性或心血管危险因素及事件)的组合可能促成对TNFi的不利反应。
关键数值与推荐
- BASDAI50定义为BASDAI评分改善至少50%。
- 女性第一线TNFi治疗随访第二年BASDAI50反应概率较低(P=0.018)。
- 逻辑回归显示女性BASDAI50反应较低(P=0.05),年龄较大与不利反应相关(P=0.004)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Real-world studies are needed to identify factors associated with response to biologic therapies in patients with axial spondyloarthritis (SpA). The objective was to assess sex differences in response to tumor necrosis factor inhibitors (TNFi) and to explore possible risk factors associated with TNFi efficacy. METHODS: A total of 969 patients with axial SpA (315 females, 654 males) enrolled in the BIOBADASER registry (2000-2019) who initiated a TNFi (first, second, or further lines) were studied. Statistical and artificial intelligence (AI)-based data analyses were used to explore the association of sex differences and other factors to TNFi response, using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), to calculate the BASDAI50, with an improvement of at least 50% of the BASDAI score, and using the Ankylosing Spondylitis Disease Activity Score, calculated using the C-reactive protein level (ASDAS-CRP). RESULTS: Females had a lower probability of reaching a BASDAI50 response with a first line TNFi treatment at the second year of follow-up (P = 0.018) and a lesser reduction of the ASDAS-CRP at this time point. The logistic regression model showed lower BASDAI50 responses to TNFi in females (P = 0.05). Other factors, such as older age (P = 0.004), were associated with unfavorable responses. The AI data analyses reinforced the idea that age at the beginning of the treatment was the main factor associated with an unfavorable response. The combination of age with other clinical characteristics (female sex or cardiovascular risk factors and events) potentially contributed to an unfavorable response to TNFi. CONCLUSION: In this national multicenter registry, female sex was associated with less response to a first-line TNFi by the second year of follow-up. A higher age at the start of the TNFi was the main factor associated with an unfavorable response to TNFi.
引用
- Fernández-Carballido C, Sanchez-Piedra C, Valls R, et al. Female Sex, Age, and Unfavorable Response to Tumor Necrosis Factor Inhibitors in Patients With Axial Spondyloarthritis: Results of Statistical and Artificial Intelligence-Based Data Analyses of a National Multicenter Prospective Registry. Arthritis Care Res (Hoboken). 2022. PMID: 36278846. doi:10.1002/acr.25048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。